7 Results for "

dual leucine zipper kinase (DLK)

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "dual leucine zipper kinase (DLK)" in MCE Product Catalog:

11
GNE-3511
GNE-3511
0 Images
11 Cited Publications
Cat. No.: HY-12947
CAS No.: 1496581-76-0
Purity:  99.54%
Target:  

MAP3K

연구분야:  

Neurological Disease

GNE-3511 is an orally active bioavailable and brain-penetrant dual leucine zipper kinase (DLK) inhibitor with a Ki of 0.5 nM. GNE-3511 can cross the blood-brain-barrier and can be used for the research of neurodegenerative diseases .
1
DN-1289
DN-1289
0 Images
1 Cited Publications
Cat. No.: HY-152142
CAS No.: 3026597-15-6
Purity:  99.63%
Target:  

JNK

연구분야:  

Neurological Disease

DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase (DLK; IC50=17 nM) and leucine zipper-bearing kinase (LZK; IC50=40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability .
GNE-8505
GNE-8505
0 Images
Cat. No.: HY-114332
CAS No.: 1620573-48-9
Purity:  99.86%
Target:  

MAP3K JNK

연구분야:  

Neurological Disease Metabolic Disease

GNE-8505 is an orally active, blood-brain barrier-permeable selective dual leucine zipper kinase (DLK) inhibitor. GNE-8505 has an IC50 of 0.144 μM for pJNK, and EC50 of 0.457 μM for DRG. GNE-8505 inhibits the DLK/JNK pathway, reduces stress-induced c-Jun phosphorylation levels, decreases neuronal death and suppresses axonal degeneration. GNE-8505 reduces phosphorylated c-Jun levels in the retina, spinal cord and brain tissues of mice. GNE-8505 is applicable to research related to Alzheimer's disease and amyotrophic lateral sclerosis (ALS) .
DLK-IN-1
DLK-IN-1
0 Images
Cat. No.: HY-114331
CAS No.: 1620574-24-4
Purity:  99.18%
Target:  

MAP3K FLT3 PAK STK33 Trk Receptor

연구분야:  

Neurological Disease

DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research .
GDC-0134
GDC-0134
0 Images
Cat. No.: HY-148629
CAS No.: 1637394-01-4
Purity:  99.18%
Target:  

JNK

연구분야:  

Neurological Disease

GDC-0134 (RG6000) is a modulator targeting dual leucine zipper kinase (DLK) that can cross the blood-brain barrier. By inhibiting the kinase activity of DLK, GDC-0134 blocks the activation of the downstream JNK signaling pathway, suppresses DLK-dependent retrograde signal transduction of axon-to-soma degeneration, and exerts neuroprotective activity. GDC-0134 reduces TDP-43 protein aggregation and decreases the degree of neuromuscular junction denervation in motor neurons. GDC-0134 can be used in the research of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other DLK-related neurodegenerative diseases .
KAI-11101
KAI-11101
0 Images
Cat. No.: HY-170484
Target:  

MAP3K p38 MAPK

연구분야:  

Neurological Disease

KAI-11101 is the inhibitor for dual leucine zipper kinase (DLK, MAP3K12) with a Ki of 0.7 nM. KAI-11101 inhibits Paclitaxel (HY-B0015)-induced cJun phosphorylation (IC50=95 nM) and thus inhibits the activation of MAPK pathway. KAI-11101 is blood brain barrier penetrable and can be further investigated for its neuroprotective property .
CEP-14083
CEP-14083
0 Images
Cat. No.: HY-14243
CAS No.: 856692-39-2
Target:  

Anaplastic lymphoma kinase (ALK) Insulin Receptor VEGFR Tie

연구분야:  

Cancer

CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC50 value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma .
Assay Types